Company History
-
SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer.
-
SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics for cancer.
-
Study of JX-594 is begun at PNUYH in patients with renal cell carcinoma (JX594-IV-REN022) , with SillaJen providing CRO services.
-
Research Collaboration Agreement signed between Pusan National University (PNU), SillaJen, and Jennerex, Inc., for oncolytic virus research to be conducted by SillaJen at PNU.
-
The multi-national “Randomized Study of JX-594 in Patients with Hepatocellular Carcinoma” (JX594-IT-HEP007) is initiated, with SillaJen providing CRO services.
-
SillaJen, Inc. is established.
-
Academic collaboration between Dr. David Kirn and Dr. Tae-Ho Hwang is initiated for the pre-clinical research of the oncolytic virus JX-594.